文献速递临床试验与 GCP

鼻敏汤治疗常年性变应性鼻炎:开放标签非劣效随机对照试验

Efficacy of Bimin decoction for patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial.
PubMed 文献 · Trials · 2019-12-30

该开放标签非劣效随机对照试验纳入108例肺气虚寒型常年性变应性鼻炎患者,随机分为鼻敏汤组和氯雷他定联合氟替卡松鼻喷剂对照组,治疗4周。结果显示鼻敏汤在改善鼻部症状总分方面非劣效于对照组,且生活质量改善更明显。

要点

  • 鼻敏汤治疗4周后鼻部症状总分较基线显著降低,且非劣效于氯雷他定联合氟替卡松鼻喷剂。
  • 鼻敏汤组生活质量问卷评分改善较对照组更明显。
  • 两组鼻阻力、鼻腔容积及鼻腔最小横截面积无显著差异。

核心结论

  • 鼻敏汤有助于缓解常年性变应性鼻炎症状并改善鼻炎相关生活质量。
  • 在肺气虚寒型变应性鼻炎患者中,鼻敏汤非劣效于氯雷他定片联合氟替卡松鼻喷剂。

研究设计与样本

  • 开放标签非劣效随机对照试验,2017年1月至2018年4月在北京中医医院通过中央计算机系统按1:1随机分组。
  • 共纳入108例19至60岁肺气虚寒型常年性变应性鼻炎患者,98例完成研究(鼻敏汤组51例,对照组47例)。
  • 鼻敏汤组接受鼻敏汤治疗,对照组接受氟替卡松鼻喷剂和氯雷他定片治疗,疗程4周。

主要发现

  • 治疗4周后两组鼻部症状总分均较基线显著降低(P < 0.05)。
  • 两组鼻部症状总分变化组间差异无统计学意义,差值为-0.298(95%置信区间-0.640至0.140),在预设非劣效界值内。
  • 两组生活质量问卷评分均较基线显著降低(P < 0.001),鼻敏汤组降低更明显(P < 0.001)。
  • 治疗后两组鼻阻力、鼻腔容积及鼻腔最小横截面积差异均无统计学意义(P > 0.05)。

关键数值与推荐

  • 主要结局为基线至治疗结束时鼻部症状总分的变化。
  • 次要结局包括鼻结膜炎生活质量问卷、鼻阻力和声反射鼻测量参数的变化。
  • 记录所有治疗相关副作用。

临床怎么用

  • 对于肺气虚寒型常年性变应性鼻炎患者,鼻敏汤可作为替代氯雷他定联合氟替卡松鼻喷剂的治疗选择。
  • 鼻敏汤在改善鼻炎相关生活质量方面可能更具优势。

局限性

  • 研究为开放标签设计,未设盲。
  • 样本量较小,完成研究98例。
  • 研究仅针对肺气虚寒型患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allergic rhinitis (AR) is a common allergic disease. It affects people worldwide and traditional Chinese medicine is becoming popular among AR patients because it has a definite clinical effect and there are few adverse reactions. Lung qi deficiency and cold syndrome (LQDCS) is a frequent type of AR, and the Chinese herbal medicine bimin decoction (BMD) is prescribed for it. This study compared the clinical efficacy of BMD for AR patients with LQDCS to the conventional medicine loratadine and fluticasone nasal spray. METHODS: The study was an open-label non-inferiority randomized controlled trial. A total of 108 AR patients with LQDCS aged 19 to 60 were randomly allocated in a 1:1 ratio to the BMD group or the control group by the central computer system in Beijing Hospital of Traditional Chinese Medicine from January 2017 to April 2018. In total, 98 participants completed the study (BMD group n = 51 and control group n = 47). Patients in the BMD group received BMD while those in the control group received fluticasone nasal spray and loratadine tablets for 4 weeks. The primary outcome was the change in the Total Nasal Symptom Score (TNSS) between the baseline and the end of treatment. Changes in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), nasal resistance, and acoustic rhinometry parameters were secondary outcomes. All side effects due to the treatments were recorded. RESULTS: After the 4-week treatment, the total TNSS was significantly reduced in both groups compared to the baseline (P < 0.05). No significant between-groups differences were observed for changes in TNSS scores [- 0.298 (95% confidence interval -0.640 to 0.140)], which was within the defined non-inferiority margin. RQLQ in both groups decreased significantly (P < 0.001) from baseline, though a more obvious reduction was observed for the BMD group (P < 0.001). There were no significant differences in nasal resistance, nasal volume, or nasal minimum cross-sectional area between groups after treatment (P > 0.05). CONCLUSIONS: These findings indicate that BMD helps relieve the symptoms of perennial AR and improves rhinitis-related quality of life. Our study indicates that BMD is non-inferior to loratadine tablets and fluticasone nasal spray for AR patients with LQDCS. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-INR-16010063. Registered on 2 December 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhao J, Yan X, Gai J, et al. Efficacy of Bimin decoction for patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial. Trials. 2019. PMID: 31888713. doi:10.1186/s13063-019-3763-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。